Table 3.
Myb immunohistochemical expression in other, non-salivary, carcinomas.
| # Cases | Myb reactivity | % positive | |
|---|---|---|---|
| Thymoma | 4 | 3 | 75% |
| Lymphoma | 7 | 5 | 71% |
| Breast carcinoma | 14 | 5 | 36% |
| Colonic adenocarcinoma | 11 | 3 | 27% |
| Testicular carcinoma | 32 | 8 | 25% |
| Head and neck squamous cell carcinoma | 11 | 2 | 18% |
| Esophageal carcinoma | 10 | 1 | 10% |
| Urothelial carcinoma | 11 | 1 | 9% |
| Ovarian carcinoma | 11 | 1 | 9% |
| Melanoma | 23 | 2 | 9% |
| Renal carcinoma | 13 | 1 | 8% |
| Brain neoplasia | 18 | 0 | 0% |
| Non small cell lung cancer | 18 | 0 | 0% |
| Liver neoplasia | 14 | 0 | 0% |
| Pancreastic neoplasia | 12 | 0 | 0% |
| Prostatic carcinoma | 12 | 0 | 0% |
| Uterine carcinoma | 11 | 0 | 0% |
| Cervical carcinoma | 10 | 0 | 0% |
| Thyroid neoplasia | 9 | 0 | 0% |
| Gastric carcinoma | 8 | 0 | 0% |
| Adrenal neoplasia | 7 | 0 | 0% |
| Mesothelioma | 5 | 0 | 0% |